Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Chembio Diagnostics is a diagnostics & research business based in the US. Chembio Diagnostics shares (CEMI) are listed on the NASDAQ and all prices are listed in US Dollars. Chembio Diagnostics employs 337 staff and has a trailing 12-month revenue of around $59.8 million.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $0.44 |
|---|---|
| 52-week range | $0.19 - $1.24 |
| 50-day moving average | $0.29 |
| 200-day moving average | $0.52 |
| Wall St. target price | $8.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.43 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.44 from 2023-02-01
| 1 week (2023-01-27) | 25.71% |
|---|---|
| 1 month (2022-12-30) | N/A |
| 3 months (2022-10-30) | N/A |
| 6 months (2022-07-30) | N/A |
| 1 year (2022-02-03) | -53.19% |
|---|---|
| 2 years (2021-02-03) | -94.02% |
| 3 years (2020-02-03) | 4.09 |
| 5 years (2018-02-02) | 8.2 |
| Revenue TTM | $59.8 million |
|---|---|
| Gross profit TTM | $12.8 million |
| Return on assets TTM | -22% |
| Return on equity TTM | -110.81% |
| Profit margin | -60.93% |
| Book value | $0.50 |
| Market capitalisation | $13.2 million |
TTM: trailing 12 months
We're not expecting Chembio Diagnostics to pay a dividend over the next 12 months.
Chembio Diagnostics's shares were split on a 1:8 basis on 29 May 2012. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Chembio Diagnostics shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Chembio Diagnostics shares which in turn could have impacted Chembio Diagnostics's share price.
Over the last 12 months, Chembio Diagnostics's shares have ranged in value from as little as $0.19 up to $1.24. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Chembio Diagnostics's is 1.7196. This would suggest that Chembio Diagnostics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Chembio Diagnostics, Inc. , together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as sells its products directly through distributors to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.